Shares of DexCom, Inc. (NASDAQ:DXCM) have been given an average rating of “Buy” by the twenty-six brokerages that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $70.69.

A number of equities analysts have recently weighed in on the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 price objective (down previously from $90.00) on shares of DexCom in a research note on Thursday, September 28th. Raymond James Financial, Inc. lowered DexCom from an “outperform” rating to a “mkt perform” rating in a research note on Friday, September 29th. Canaccord Genuity reissued a “buy” rating and set a $69.00 price target (down from $90.00) on shares of DexCom in a research note on Thursday, September 28th. TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. Finally, Zacks Investment Research raised DexCom from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th.

DexCom (NASDAQ DXCM) traded up $4.26 during midday trading on Wednesday, hitting $49.12. The stock had a trading volume of 1,720,582 shares, compared to its average volume of 1,705,606. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.84.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%. The business’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.24) earnings per share. research analysts forecast that DexCom will post -0.74 EPS for the current year.

In other news, EVP Andrew K. Balo sold 3,244 shares of DexCom stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $71.18, for a total value of $230,907.92. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $44.82, for a total value of $73,280.70. Following the completion of the transaction, the executive vice president now owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold a total of 23,208 shares of company stock worth $1,597,567 over the last 90 days. 1.70% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of DXCM. UBS Group AG boosted its position in shares of DexCom by 11.1% in the 1st quarter. UBS Group AG now owns 20,317 shares of the medical device company’s stock worth $1,721,000 after purchasing an additional 2,038 shares in the last quarter. BlackRock Inc. lifted its position in DexCom by 5,000.4% during the 1st quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock worth $352,550,000 after acquiring an additional 4,079,283 shares during the period. Schwab Charles Investment Management Inc. lifted its position in DexCom by 3.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 227,240 shares of the medical device company’s stock worth $19,255,000 after acquiring an additional 6,813 shares during the period. State Street Corp lifted its position in DexCom by 1.9% during the 1st quarter. State Street Corp now owns 1,512,262 shares of the medical device company’s stock worth $128,127,000 after acquiring an additional 28,311 shares during the period. Finally, AQR Capital Management LLC lifted its position in DexCom by 12.3% during the 1st quarter. AQR Capital Management LLC now owns 74,211 shares of the medical device company’s stock worth $6,288,000 after acquiring an additional 8,137 shares during the period.

WARNING: “Brokerages Set DexCom, Inc. (DXCM) Target Price at $72.38” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/brokerages-set-dexcom-inc-dxcm-target-price-at-72-38/1678821.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.